摘要
大麻素受体1(cannabinoid receptor 1,CB1)和大麻素受体2(cannabinoid receptor 2,CB_2)可以形成同源二聚体,也可以与多种受体形成异源二聚体。异源二聚体大大增加了G蛋白偶联受体(G proteincoupled receptors,GPCRs)功能反应的范畴,对药物的开发存在很大的潜力。异源二聚体具有不同于单体和同源二聚体的高阶结构特点[1],CB1受体。
Cannabinoid receptor 1( CB1) and cannabinoid receptor 2( CB_2) are important members of G protein-coupled receptors( GPCRs). Numerous studies have shown that CB_1 receptor can form heterodimers with dopamine receptors( D2),μ-opioid receptor( μOR),orexin-1 receptor,adenosine receptor( A_(2A)) or β2 adrenergic receptors,and then forming an essential functional entity. This review summarizes the research progress on heterodimers of cannabinoid CB1 or CB_2,the function of heterodimers as well as the downstream signalings. The different pharmacological properties of the receptor heterodimer lead to bringing a change in receptor pharmacology,which will have a profound impact on drug development.
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2016年第1期172-178,共7页
Chinese Journal of Pathophysiology
基金
国家自然科学基金资助项目(No.81473342
No.U130225)
云南省人培基金(No.KKSY201326116)
云南省高端科技人才基金(No.2012HA008)
关键词
大麻素受体
二聚化
Cannabinoid receptor
Dimerization